BR112019024831A2 - composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3 - Google Patents

composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3 Download PDF

Info

Publication number
BR112019024831A2
BR112019024831A2 BR112019024831A BR112019024831A BR112019024831A2 BR 112019024831 A2 BR112019024831 A2 BR 112019024831A2 BR 112019024831 A BR112019024831 A BR 112019024831A BR 112019024831 A BR112019024831 A BR 112019024831A BR 112019024831 A2 BR112019024831 A2 BR 112019024831A2
Authority
BR
Brazil
Prior art keywords
prodrug
solvate
disease
treating
salt
Prior art date
Application number
BR112019024831A
Other languages
English (en)
Inventor
O'neill Luke
Coll Rebecca
Cooper Matthew
Robertson Avril
Schroder Kate
Murray Macleod Angus
John Miller David
Original Assignee
The University Of Queensland
The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Queensland, The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin filed Critical The University Of Queensland
Publication of BR112019024831A2 publication Critical patent/BR112019024831A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/59—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)

Abstract

a presente invenção refere-se a compostos de fórmula (i): em que q é o ou s; r1 é um grupo cíclico substituído com pelo menos um grupo x, em que r1 pode opcionalmente ser ainda mais substituído; x é qualquer grupo compreendendo um grupo carbonila; e r2 é um grupo cíclico substituído na posição a, em que r2 pode opcionalmente ser adicionalmente substituído. a presente invenção refere-se ainda a sais, solvatos e prófármacos de tais compostos, a composições farmacêuticas que compreendem esses compostos e ao uso de tais compostos no tratamento e prevenção de distúrbios e doenças médicas, principalmente pela ação dupla da inibição de nlrp3 e a estimulação da secreção de insulina.
BR112019024831A 2017-05-24 2017-05-24 composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3 BR112019024831A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2017/053059 WO2018215818A1 (en) 2017-05-24 2017-05-24 Novel compounds and uses

Publications (1)

Publication Number Publication Date
BR112019024831A2 true BR112019024831A2 (pt) 2020-06-09

Family

ID=64396390

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024831A BR112019024831A2 (pt) 2017-05-24 2017-05-24 composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3

Country Status (8)

Country Link
US (1) US11840543B2 (pt)
JP (1) JP7072586B2 (pt)
AR (1) AR109349A1 (pt)
AU (1) AU2017416068A1 (pt)
BR (1) BR112019024831A2 (pt)
CA (1) CA3059458A1 (pt)
UY (1) UY37363A (pt)
WO (1) WO2018215818A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10538487B2 (en) 2015-02-16 2020-01-21 The University Of Queensland Sulfonylureas and related compounds and use of same
BR112018016671A2 (pt) 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
CR20190356A (es) 2017-01-23 2019-11-20 Genentech Inc Compuestos químicos como inhibidores de la actividad de la interleuquina-1
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
HRP20220195T1 (hr) 2017-07-07 2022-04-15 Inflazome Limited Novi spojevi sulfonamid karboksamida
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
JP2020531453A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア
WO2019034692A1 (en) * 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
JP2020531448A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
WO2019092171A1 (en) * 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3707134A1 (en) * 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166619A1 (en) * 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
WO2019166633A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Sulfonamide derivates as nlrp3 inhibitors
WO2019166629A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
CA3099080A1 (en) 2018-05-04 2019-11-07 Inflazome Limited Novel compounds
EP3823726A1 (en) 2018-07-20 2021-05-26 F. Hoffmann-La Roche SA Sulfonylurea compounds as inhibitors of interleukin-1 activity
CR20210139A (es) 2018-08-15 2021-06-24 Inflazome Ltd Compuestos de sulfonamidaurea novedosos
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
WO2020157069A1 (en) * 2019-01-28 2020-08-06 NodThera Limited Amino heterocyclic compounds and uses thereof
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
WO2020254697A1 (en) 2019-06-21 2020-12-24 Ac Immune Sa Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators
WO2021002887A1 (en) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy
AU2020312800A1 (en) * 2019-07-17 2022-02-24 Zomagen Biosciences Ltd N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms)
US20220289766A1 (en) 2019-08-16 2022-09-15 Inflazome Limited Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitors
WO2021043966A1 (en) 2019-09-06 2021-03-11 Inflazome Limited Nlrp3 inhibitors
WO2021093820A1 (zh) * 2019-11-12 2021-05-20 成都百裕制药股份有限公司 酰胺衍生物及其制备方法和在医药上的应用
WO2021165245A1 (en) 2020-02-18 2021-08-26 Inflazome Limited Compounds
WO2021188450A1 (en) * 2020-03-16 2021-09-23 Zomagen Biosciences Ltd Nlrp3 modulators
CN111419842A (zh) * 2020-04-24 2020-07-17 南方医科大学南方医院 炎症小体抑制剂cy-09用于制备治疗非酒精性脂肪性肝炎的药物的用途
MX2022014709A (es) 2020-06-19 2022-12-16 Ac Immune Sa Derivados de dihidrooxazol y tiourea que modulan la ruta del inflamasoma de la proteina 3 que contiene el dominio pirina de la familia del receptor similar al dominio de oligomerizacion de union a nucleotido (nlrp3).
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
EP3984535A1 (en) * 2020-10-16 2022-04-20 Albert-Ludwigs-Universität Freiburg Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
CN118541366A (zh) 2021-12-22 2024-08-23 Ac免疫有限公司 二氢噁唑衍生物化合物
WO2024013395A1 (en) 2022-07-14 2024-01-18 Ac Immune Sa Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
WO2024023266A1 (en) 2022-07-28 2024-02-01 Ac Immune Sa Novel compounds
CN115227879B (zh) * 2022-09-15 2023-01-06 北京天星博迈迪医疗器械有限公司 一种用于可降解关节球囊的组合物及其应用、一种可降解关节球囊及其制备方法

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797474A (en) 1955-07-20 1958-07-02 Boehringer & Soehne Gmbh Sulphonylurea derivatives
DE1012598B (de) 1955-07-20 1957-07-25 Boehringer & Soehne Gmbh Verfahren zur Herstellung von oral wirksamen Antidiabetika
DE1168415B (de) 1962-04-06 1964-04-23 Boehringer & Soehne Gmbh Verfahren zur Herstellung neuer Benzolsulfonyl-semicarbazide
DE1185180B (de) 1963-10-19 1965-01-14 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
DE1518874C3 (de) 1964-10-07 1975-03-13 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt Benzolsulfonylharnstoffe und Verfahren zu ihrer Herstellung
DE1618402B2 (de) * 1966-05-28 1976-08-19 Hoechst Ag, 6000 Frankfurt Benzolsulfonylharnstoffe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE1670121A1 (de) 1966-08-02 1970-10-29 Boehringer Mannheim Gmbh Verfahren zur Herstellung neuer antidiabetisch wirksamer Benzolsulfonyl-semicarbazide
CH509992A (de) 1966-08-08 1971-07-15 Hoffmann La Roche Verfahren zur Herstellung von Sulfonamiden
NL131473C (pt) 1966-10-28
US3917690A (en) * 1966-11-29 1975-11-04 Hoechst Ag Benzenesulfonyl ureas and process for their manufacture
DE1568626C3 (de) * 1966-11-29 1975-11-20 Hoechst Ag, 6000 Frankfurt Benzolsulfonyl-harnstoffe, ihre Salze, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
CH484144A (de) 1967-09-15 1970-01-15 Geigy Ag J R Verfahren zur Herstellung von neuen Sulfonylharnstoffen
GB1203125A (en) 1968-10-30 1970-08-26 Jerrold Electronics Corp A grounded collector amplifier circuit
BE754588A (fr) 1969-08-07 1971-02-08 Hoechst Ag Thiophene-sulfonyl-urees et les medicaments qui contiennent cessubstances
GB2110689A (en) 1981-12-03 1983-06-22 Sandoz Ltd Herbicidal heterocyclic aminosulfonyl ureas and isoureas
AU571869B2 (en) 1983-05-09 1988-04-28 E.I. Du Pont De Nemours And Company Pyridyl- and pyrimidyl- sulphonamides
EP0126711B1 (de) 1983-05-16 1989-08-02 Ciba-Geigy Ag Herbizid wirksame und pflanzenwuchsregulierende Pyrimidin-Derivate, deren Herstellung und Verwendung
JPS6045573A (ja) 1983-08-22 1985-03-12 Nissan Chem Ind Ltd ピラゾ−ルスルホニルウレア誘導体，その製法および該誘導体を含有する選択性除草剤
US4723991A (en) 1984-03-23 1988-02-09 E. I. Du Pont De Nemours And Company Lower alkyl 2-[[N-(3-cyano-pyridin-2-yl)aminocarbonyl]aminosulphonyl]benzoate derivatives having herbicidal activity
US4659369A (en) 1984-08-27 1987-04-21 E. I. Du Pont De Nemours And Company Herbicidal acetals and ketals
AU578307B2 (en) 1984-09-17 1988-10-20 E.I. Du Pont De Nemours And Company Herbicidal pyrazolesulfonamides
FI855180A (fi) 1985-01-18 1986-07-19 Nissan Chemical Ind Ltd Pyrazolsulfonamidderivat, foerfarande foer dess framstaellande och det innehaollande ograesgift.
JPH0720958B2 (ja) 1985-01-18 1995-03-08 日産化学工業株式会社 ピラゾ−ルスルホンアミド誘導体、製法および除草剤
CA1231336A (en) 1985-05-30 1988-01-12 George Levitt Herbicidal sulfonamides
JPS6216457A (ja) 1985-06-12 1987-01-24 イ−・アイ・デユポン・デ・ニモアス・アンド・カンパニ− 除草剤性スルホンアミド類
US4889550A (en) 1985-06-12 1989-12-26 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
US4678498A (en) 1985-06-12 1987-07-07 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
JPH0720957B2 (ja) 1985-11-26 1995-03-08 日産化学工業株式会社 ピラゾ−ルスルホニルウレア誘導体、製法および除草剤
JP2570686B2 (ja) 1985-12-23 1997-01-08 日産化学工業株式会社 ピラゾ−ル誘導体
US4830660A (en) 1986-06-19 1989-05-16 Nissan Chemical Industries, Ltd. Imidazolesulfonamide derivatives and herbicides
DE3775686D1 (de) 1986-09-26 1992-02-13 Ciba Geigy Ag Aminopyrazinone und aminotriazinone.
US4802908A (en) 1987-01-22 1989-02-07 E. I. Du Pont De Nemours And Company Herbicidal 2-(1H)-pyrazinones
US5411980A (en) 1989-07-28 1995-05-02 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
US5356862A (en) 1990-01-22 1994-10-18 E. I. Du Pont De Nemours And Company Herbicidal sulfonylureas
WO1992004319A1 (en) 1990-08-29 1992-03-19 E.I. Du Pont De Nemours And Company Herbicidal pyrrolesulfonylureas
US5484760A (en) 1990-12-31 1996-01-16 Monsanto Company Herbicide antidotes as safeners for reducing phytotoxicity resulting from synergistic interaction between herbicides and other pesticides
EP0555770A1 (de) 1992-02-14 1993-08-18 Hoechst Schering AgrEvo GmbH N-Heteroaryl-N'-(pyrid-2-yl-sulfonyl)-harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und Pflanzenwachstumsregulatoren
DE69622148T2 (de) 1995-09-28 2002-10-31 Suntory Limited, Osaka Chinazozin derivate und deren verwendung
AU1735497A (en) 1996-02-26 1997-09-10 Sumitomo Pharmaceuticals Company, Limited Sulfonylureidopyrazole derivatives
ATE242208T1 (de) * 1997-01-29 2003-06-15 Pfizer Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität
JP2000053649A (ja) 1998-08-11 2000-02-22 Sumitomo Pharmaceut Co Ltd スルホニルウレイドピラゾール誘導体
KR20010089168A (ko) 1998-08-21 2001-09-29 도리이 신이치로 퀴나졸린 유도체 및 이의 약제학적 용도
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
WO2001019390A1 (en) 1999-09-14 2001-03-22 Pfizer Products Inc. Combination treatment with il-1ra and diaryl sulphonyl urea compounds
ATE360423T1 (de) 1999-11-01 2007-05-15 Daiichi Asubio Pharma Co Ltd Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
HUP0201284A3 (en) 2000-02-22 2003-02-28 Daiichi Asubio Pharma Co Ltd Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient
DE60126199T2 (de) 2000-02-22 2008-02-28 Asubio Pharma Co., Ltd. Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktive bestandteile
WO2001062294A1 (fr) 2000-02-22 2001-08-30 Suntory Limited Medicaments preventifs ou therapeutiques contenant des inhibiteurs de chymase en tant que principe actif, pour traiter des dermatites
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
CA2463272C (en) 2001-10-22 2009-11-17 Laura Cook Blumberg Piperazine derivatives with ccr1 receptor antagonist activity
WO2003045400A1 (en) 2001-11-30 2003-06-05 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
WO2003086563A2 (en) 2002-04-11 2003-10-23 Carbomer, Inc. Diabetes imaging probes
US20040092529A1 (en) 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
AR052900A1 (es) 2005-02-11 2007-04-11 Astrazeneca Ab Derivados de tiazol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades mediadas por ece-1
CN102791712B (zh) 2010-03-05 2015-07-01 协和发酵麒麟株式会社 吡唑并嘧啶衍生物
WO2013031931A1 (ja) 2011-09-02 2013-03-07 協和発酵キリン株式会社 ケモカイン受容体活性調節剤
TW201501713A (zh) 2013-03-01 2015-01-16 Kyowa Hakko Kirin Co Ltd 眼炎症性疾病之預防及／或治療劑
US10538487B2 (en) 2015-02-16 2020-01-21 The University Of Queensland Sulfonylureas and related compounds and use of same
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
BR112018016671A2 (pt) 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
EP3872070A1 (en) 2016-04-18 2021-09-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
CN105906535B (zh) 2016-05-16 2018-10-16 沈阳农业大学 保护农作物免受除草剂药害的安全剂、组合剂及使用方法
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
CR20190356A (es) 2017-01-23 2019-11-20 Genentech Inc Compuestos químicos como inhibidores de la actividad de la interleuquina-1
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
HRP20220195T1 (hr) 2017-07-07 2022-04-15 Inflazome Limited Novi spojevi sulfonamid karboksamida
JP2020531448A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
WO2019034692A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
JP2020531453A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア
US20210122739A1 (en) 2017-08-15 2021-04-29 Inflazome Limited Novel sulfonamide carboxamide compounds
RU2020110366A (ru) 2017-08-15 2021-09-16 Инфлазоум Лимитед Новые соединения сульфонамидкарбоксамидов
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3707134A1 (en) 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019092172A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019166629A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
US20200399242A1 (en) 2018-03-02 2020-12-24 Inflazome Limited Novel compounds
WO2019166633A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Sulfonamide derivates as nlrp3 inhibitors
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
CA3099080A1 (en) 2018-05-04 2019-11-07 Inflazome Limited Novel compounds
CR20210139A (es) 2018-08-15 2021-06-24 Inflazome Ltd Compuestos de sulfonamidaurea novedosos
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
EP4013762A1 (en) 2019-08-16 2022-06-22 Inflazome Limited Macrocyclic sulfonylamide derivatives useful as nlrp3 inhibitors
US20220289766A1 (en) 2019-08-16 2022-09-15 Inflazome Limited Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitors
WO2021043966A1 (en) 2019-09-06 2021-03-11 Inflazome Limited Nlrp3 inhibitors
WO2021165245A1 (en) 2020-02-18 2021-08-26 Inflazome Limited Compounds

Also Published As

Publication number Publication date
WO2018215818A1 (en) 2018-11-29
UY37363A (es) 2019-01-02
US20200207780A1 (en) 2020-07-02
US11840543B2 (en) 2023-12-12
CA3059458A1 (en) 2018-11-29
JP2020520984A (ja) 2020-07-16
JP7072586B2 (ja) 2022-05-20
AU2017416068A1 (en) 2019-10-31
AR109349A1 (es) 2018-11-21

Similar Documents

Publication Publication Date Title
BR112019024831A2 (pt) composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
UY37845A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
BR112019000247A2 (pt) derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
BR112019016291A2 (pt) novo composto heterocíclico, seu método de preparação e composição farmacêutica compreendendo o mesmo
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112019007763A2 (pt) composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
BR112015012693A2 (pt) derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112012021453A2 (pt) tienopirimidina, sua composição farmacêutica e seu uso
BR112018073524A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição.
BR112015020600A2 (pt) composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112018010107A8 (pt) Composição farmacêutica para o tratamento ou prevenção de nash
BR112015026410A2 (pt) derivados de dolastatina 10 e auristatinas
BR112020008258B8 (pt) Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido)
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2776 DE 19/03/2024.